Continues to be a top pick for 2026 due to the explosive demand for Zepbound and Mounjaro . Analysts at JPMorgan view Lilly as a preferred large-cap name with significant volume growth potential.
Growth in 2026 is largely driven by companies with dominant market shares in weight loss and diabetes, as well as those successfully refreshing their pipelines. pharma stocks to buy
For defensive positioning, these "Dividend Kings" and established giants offer high yields and reliable cash flows. Got $500? 2 Pharma Stocks to Buy and Hold Forever. Continues to be a top pick for 2026
A dominant player in the GLP-1 space alongside Lilly. The anticipated launch of its Wegovy pill in early 2026 is expected to unlock massive volume and maintain its leadership in obesity care. A dominant player in the GLP-1 space alongside Lilly
Highlighted as a stock to watch due to its promising obesity candidate, MariTide , which offers a potentially less frequent dosing schedule than existing competitors. Top Income & Stability Picks